Biotech Values

[DewDiligence]

After the Vytorin-induced sell-off, SGP is trading at a modest valuation relative to expected sales and earnings. If it falls much further, SGP could become an attractive takeover candidate based on the HCV franchise and the antiplatelet drug candidate (#msg-23899164).

On the other hand, SGP’s recent acquisition of Organon makes a takeover of SGP less likely than it otherwise would be, IMO.